Analysis | Samples | Factors | Units |
---|---|---|---|
GC POSITIVE ION MODE | BM_supernatant_5FU_1 | Source_Name[gating]:Bone marrow supernatant | Treatment:5 FU 2 weeks | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | BM_supernatant_5FU_2 | Source_Name[gating]:Bone marrow supernatant | Treatment:5 FU 2 weeks | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | BM_supernatant_5FU_3 | Source_Name[gating]:Bone marrow supernatant | Treatment:5 FU 2 weeks | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | BM_supernatant_Ctrl_1 | Source_Name[gating]:Bone marrow supernatant | Treatment:HSC Basal | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | BM_supernatant_Ctrl_2 | Source_Name[gating]:Bone marrow supernatant | Treatment:HSC Basal | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | BM_supernatant_Ctrl_3 | Source_Name[gating]:Bone marrow supernatant | Treatment:HSC Basal | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_0h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_0h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_0h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_12h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_12h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_12h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_6h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_6h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_5FU_6h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_0h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_0h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_0h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_6h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_12h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_12h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_12h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_6h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Cultured_6h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_0h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_0h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_0h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_12h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_12h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_12h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_6h_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_6h_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_6h_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |
GC POSITIVE ION MODE | HSC_Ctrl_3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). | Peak Area |